Abstract
Rheumatoid arthritis (RA) and the various types of spondylarthritis (SpA) contribute significantly to employee disability. Each of these inflammatory diseases has a great impact on physical and mental health, thereby restricting one's ability to participate in one's social roles. This may result in decreased productivity during working hours (sickness presenteeism), absenteeism and eventually, disablement, with financial consequences for the patient as well as society. By incorporating biologicals into treatment strategies, the health of patients with RA and SpA can be better regulated; however, the cost of such treatment has risen considerably. There are indications that part of these high treatment expenditures can be regained by improved employee productivity of these patients.
| Original language | Dutch |
|---|---|
| Pages (from-to) | A3503 |
| Number of pages | 6 |
| Journal | Nederlands tijdschrift voor geneeskunde |
| Volume | 155 |
| Issue number | 30-31 |
| Publication status | Published - 2011 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
-
SDG 16 Peace, Justice and Strong Institutions
Keywords
- Arthritis, Rheumatoid/complications
- Biological Products/economics
- Cost of Illness
- Cost-Benefit Analysis
- Humans
- Sick Leave
- Social Behavior
- Spondylarthritis/complications
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver